Use of Acid-Suppression Therapy Linked to Migraine, Severe Headache
By Elana Gotkine HealthDay Reporter
FRIDAY, April 26, 2024 -- Use of acid-suppression therapy is associated with higher odds of migraine or severe headache, according to a study published online April 24 in Neurology: Clinical Practice.
Margaret Slavin, Ph.D., from the University of Maryland in College Park, and colleagues examined the association between migraine and severe headache prevalence and use of acid-suppression therapy. Data were obtained from adults in the 1999 to 2004 National Health and Nutrition Examination Survey.
The researchers found that use of acid-suppression therapy was associated with higher odds of migraine or severe headache in 11,818 U.S. adults, with higher odds for all types of acid-suppression therapy and use of any type versus nonuse (adjusted odds ratios [95 percent confidence intervals], 1.70 [1.32 to 2.18], 1.40 [1.00 to 1.95], and 1.30 [1.05 to 1.61] with use of proton pump inhibitors, H2 receptor antagonists, and generic antacids, respectively). No significant differences were seen between acid-suppression therapies. There was an interaction observed for H2 receptor antagonist use with magnesium intake.
"These results suggest that there is a need for more intentionally designed prospective work to inform the extent to which associations between migraine and acid-suppression therapy are merely detecting comorbidities or to what extent migraine is an adverse event associated with the medications," the authors write.
One author disclosed ties to the pharmaceutical industry.
Abstract/Full Text (subscription or payment may be required)
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2024 HealthDay. All rights reserved.
Posted April 2024
Read this next
Targeted Diagnostic Botox Injections Can Identify Trigger Sites for Migraine
THURSDAY, May 9, 2024 -- Diagnostic targeted Botox injections have high positive predictive value for migraine trigger site localization, according to a study published in the May...
Novel Score Validated for Diagnosis of Gastroesophageal Reflux Disease
MONDAY, May 6, 2024 -- A novel high-resolution manometry (HRM) score can stratify the risk and severity of gastroesophageal reflux disease (GERD), according to a study published...
American Academy of Neurology, April 13-18
The annual meeting of the American Academy of Neurology was held this year from April 13 to 18 in Denver, drawing participants from around the world, including clinicians...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.